AR043987A1 - Composiciones farmaceuticas para administracion oral de agonistas del receptor de fosfato de esfingosina-1 - Google Patents

Composiciones farmaceuticas para administracion oral de agonistas del receptor de fosfato de esfingosina-1

Info

Publication number
AR043987A1
AR043987A1 ARP040101162A ARP040101162A AR043987A1 AR 043987 A1 AR043987 A1 AR 043987A1 AR P040101162 A ARP040101162 A AR P040101162A AR P040101162 A ARP040101162 A AR P040101162A AR 043987 A1 AR043987 A1 AR 043987A1
Authority
AR
Argentina
Prior art keywords
sphingosine
oral administration
agonists
pharmaceutical compositions
phosphate receptor
Prior art date
Application number
ARP040101162A
Other languages
English (en)
Spanish (es)
Original Assignee
Novartis Ag
Mitsubishi Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32326722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR043987(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Mitsubishi Pharma Corp filed Critical Novartis Ag
Publication of AR043987A1 publication Critical patent/AR043987A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
ARP040101162A 2003-04-08 2004-04-06 Composiciones farmaceuticas para administracion oral de agonistas del receptor de fosfato de esfingosina-1 AR043987A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46121503P 2003-04-08 2003-04-08

Publications (1)

Publication Number Publication Date
AR043987A1 true AR043987A1 (es) 2005-08-17

Family

ID=32326722

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP040101162A AR043987A1 (es) 2003-04-08 2004-04-06 Composiciones farmaceuticas para administracion oral de agonistas del receptor de fosfato de esfingosina-1
ARP100103930A AR078781A2 (es) 2003-04-08 2010-10-26 Composicion farmaceutica solida adecuada para administracion oral
ARP100103931A AR078782A2 (es) 2003-04-08 2010-10-26 Procedimiento para producir una composicion farmaceutica que comprende un agonista del receptor de fosfato de esfingosina-1 (s1p)

Family Applications After (2)

Application Number Title Priority Date Filing Date
ARP100103930A AR078781A2 (es) 2003-04-08 2010-10-26 Composicion farmaceutica solida adecuada para administracion oral
ARP100103931A AR078782A2 (es) 2003-04-08 2010-10-26 Procedimiento para producir una composicion farmaceutica que comprende un agonista del receptor de fosfato de esfingosina-1 (s1p)

Country Status (41)

Country Link
US (11) US20060275357A1 (cg-RX-API-DMAC10.html)
EP (5) EP2319502A1 (cg-RX-API-DMAC10.html)
JP (3) JP5495467B2 (cg-RX-API-DMAC10.html)
KR (3) KR20110005320A (cg-RX-API-DMAC10.html)
CN (2) CN101797241B (cg-RX-API-DMAC10.html)
AR (3) AR043987A1 (cg-RX-API-DMAC10.html)
AT (3) ATE414508T1 (cg-RX-API-DMAC10.html)
AU (1) AU2004228929B2 (cg-RX-API-DMAC10.html)
BE (2) BE1015972A5 (cg-RX-API-DMAC10.html)
BR (1) BRPI0409250B8 (cg-RX-API-DMAC10.html)
CA (2) CA2707750A1 (cg-RX-API-DMAC10.html)
CL (2) CL2004000745A1 (cg-RX-API-DMAC10.html)
CY (3) CY1110260T1 (cg-RX-API-DMAC10.html)
DE (4) DE102004016947A1 (cg-RX-API-DMAC10.html)
DK (2) DK1613288T3 (cg-RX-API-DMAC10.html)
EC (1) ECSP056090A (cg-RX-API-DMAC10.html)
ES (3) ES2556947T3 (cg-RX-API-DMAC10.html)
FR (2) FR2854073B1 (cg-RX-API-DMAC10.html)
GB (1) GB2400318B (cg-RX-API-DMAC10.html)
GR (1) GR1005052B (cg-RX-API-DMAC10.html)
HR (3) HRP20100600A2 (cg-RX-API-DMAC10.html)
HU (2) HUE028247T2 (cg-RX-API-DMAC10.html)
IL (3) IL170888A (cg-RX-API-DMAC10.html)
IS (2) IS2682B (cg-RX-API-DMAC10.html)
IT (1) ITMI20040682A1 (cg-RX-API-DMAC10.html)
LU (1) LU91867I2 (cg-RX-API-DMAC10.html)
MA (1) MA27729A1 (cg-RX-API-DMAC10.html)
MX (1) MXPA05010860A (cg-RX-API-DMAC10.html)
MY (1) MY141249A (cg-RX-API-DMAC10.html)
NO (4) NO329332B1 (cg-RX-API-DMAC10.html)
NZ (3) NZ542622A (cg-RX-API-DMAC10.html)
PE (5) PE20150676A1 (cg-RX-API-DMAC10.html)
PL (2) PL2316431T3 (cg-RX-API-DMAC10.html)
PT (1) PT1613288E (cg-RX-API-DMAC10.html)
RU (5) RU2358716C2 (cg-RX-API-DMAC10.html)
SG (1) SG175449A1 (cg-RX-API-DMAC10.html)
SI (2) SI2316431T1 (cg-RX-API-DMAC10.html)
TN (1) TNSN05256A1 (cg-RX-API-DMAC10.html)
TW (1) TWI332847B (cg-RX-API-DMAC10.html)
WO (1) WO2004089341A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA200507394B (cg-RX-API-DMAC10.html)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007001236A (es) * 2004-07-30 2007-03-23 Novartis Ag Formulaciones de compuestos de 2-amino-1, 3-propanodiol.
CN1891212B (zh) * 2005-07-07 2010-10-13 马启明 一种口服制剂及其制备方法
WO2007028821A2 (en) * 2005-09-09 2007-03-15 Novartis Ag Treatment of autoimmune diseases
JP5436860B2 (ja) 2005-11-09 2014-03-05 オニキス セラピューティクス， インク． 酵素阻害のための化合物
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
WO2007149512A2 (en) 2006-06-19 2007-12-27 Proteolix, Inc. Peptide epoxyketones for pr0teas0me inhibition
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
AU2011235934A1 (en) * 2006-09-26 2011-11-03 Novartis Ag Pharmaceutical compositions comprising an S1P modulator
EP1923054A1 (en) * 2006-09-26 2008-05-21 Novartis AG Fast disintegrating pharmaceutical composition comprising an S1P agonist or modulator
EP1923058A1 (en) * 2006-09-26 2008-05-21 Novartis AG Coated pharmaceutical composition comprising an S1P agonist or modulator
BRPI0717570B8 (pt) * 2006-09-26 2021-05-25 Novartis Ag composição farmacêutica sólida adequada para administração oral, seu uso e seu processo de produção
EP1905434A1 (en) * 2006-09-26 2008-04-02 Novartis AG Organic compounds comprising an S1P receptor agonist and their therapeutic use
EP1923055A1 (en) * 2006-09-26 2008-05-21 Novartis AG Freeze-dried pharmaceutical composition comprising an S1P agonist or modulator
WO2008124210A1 (en) * 2007-02-14 2008-10-16 Emory University Methods and compositions for treating or preventing infection using leukocyte sequestration agents
ES2644803T5 (es) * 2007-03-29 2024-02-26 Daiichi Sankyo Co Ltd Composición farmacéutica
MY173938A (en) 2007-10-04 2020-02-27 Onyx Therapeutics Inc Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
MY159358A (en) * 2007-10-12 2016-12-30 Novartis Ag Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators
AU2012216630B2 (en) * 2007-10-12 2015-01-22 Novartis Ag Compositions comprising sphingosine 1 phosphate (S1P) receptor modulators
JP5534645B2 (ja) * 2008-01-11 2014-07-02 日医工株式会社 無包装状態において安定性に優れた塩酸サルポグレラート含有経口投与製剤
WO2009099174A1 (ja) 2008-02-07 2009-08-13 Kyorin Pharmaceutical Co., Ltd. アミノアルコール誘導体を有効成分とする炎症性腸疾患の治療剤又は予防剤
SI2278960T2 (sl) 2008-03-17 2020-02-28 Actelion Pharmaceuticals Ltd. Režim odmerjanja za selektivni agonist receptorja sip1
EP3545953A1 (en) 2008-06-20 2019-10-02 Novartis AG Paediatric compositions for treating1 multiple sclerosis
RU2519768C2 (ru) * 2008-06-20 2014-06-20 Мерк Патент Гмбх Поддающаяся прямому прессованию и быстро распадающаяся матрица таблетки
CN102143692A (zh) * 2008-09-04 2011-08-03 卡吉尔公司 赤藓醇的压片
AU2009308516B2 (en) 2008-10-21 2016-08-25 Onyx Therapeutics, Inc. Combination therapy with peptide epoxyketones
AU2013100533B4 (en) * 2008-11-11 2013-12-12 Novartis Ag Crystalline forms of fingolimod HCL
JP2012508216A (ja) * 2008-11-11 2012-04-05 ノバルティス アーゲー 有機化合物
KR20110086142A (ko) 2008-11-11 2011-07-27 노파르티스 아게 핑골리모드의 염
JP5305421B2 (ja) 2008-12-17 2013-10-02 第一三共株式会社 ジアミン誘導体の製造方法
EP2383272A4 (en) 2009-01-13 2012-07-25 Daiichi Sankyo Co Ltd ACTIVE BLOOD CREATION FACTOR HEMMER
ES2542236T3 (es) 2009-03-10 2015-08-03 Daiichi Sankyo Company, Limited Procedimiento de producción de un derivado de diamina
ES2542237T3 (es) 2009-03-13 2015-08-03 Daiichi Sankyo Company, Limited Procedimiento de producción de un derivado de diamina ópticamente activo
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
RU2012101649A (ru) * 2009-06-18 2013-07-27 Дайити Санкио Компани, Лимитед Фармацевтическая композиция, обладающая улучшенной растворимостью
US9675566B2 (en) 2009-07-16 2017-06-13 Pathologica Llc Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
US8853147B2 (en) 2009-11-13 2014-10-07 Onyx Therapeutics, Inc. Use of peptide epoxyketones for metastasis suppression
BR112012022060A2 (pt) 2010-03-01 2018-05-08 Onyx Therapeutics Inc composto para a inibição de imunoproteassoma
CA2793525C (en) 2010-03-19 2014-05-06 Daiichi Sankyo Company, Limited Method for improving dissolution of anticoagulant agent
CN102791719B (zh) 2010-03-19 2015-07-29 第一三共株式会社 二胺衍生物的晶体及其制备方法
EP2560619A2 (en) * 2010-04-22 2013-02-27 Ratiopharm GmbH A method of preparing an oral dosage form comprising fingolimod
BR112013000085B1 (pt) 2010-07-02 2022-04-19 Daiichi Sankyo Company, Limited Processos para a preparação de sal de derivado de diamina opticamente ativo
US9266816B2 (en) 2010-11-25 2016-02-23 Shilpa Medicare Limited Fingolimod polymorphs and their processes
HUE045612T2 (hu) 2011-01-07 2020-01-28 Novartis Ag Immunszuppresszáns készítmények
WO2012100043A2 (en) 2011-01-19 2012-07-26 Pathlogica LLC Controlled release oral pharmaceutical dosage forms comprising mgbg
JO3177B1 (ar) 2011-04-01 2018-03-08 Novartis Ag تركيبات تتالف من 2-أمينو-2- [ 2- ( 4- أكتيل فينيل ) إثيل ] بروبان - 3, 1- ديول
EA028950B1 (ru) 2011-08-01 2018-01-31 Тева Фармасьютикал Индастриз Лтд. Способ получения фармацевтических композиций, содержащих финголимод
BR112014002397B1 (pt) 2011-08-10 2021-08-03 Daiichi Sankyo Company, Limited Formulação sólida na forma de tablete ou cápsula contendo derivado de diamida
WO2013091704A1 (en) 2011-12-22 2013-06-27 Synthon Bv Pharmaceutical composition comprising fingolimod
RU2482842C1 (ru) * 2012-04-26 2013-05-27 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний (варианты) и способ ее получения
RU2506949C1 (ru) * 2012-06-13 2014-02-20 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
US20140105921A1 (en) 2012-07-09 2014-04-17 Onyx Therapeutics, Inc. Prodrugs of Peptide Epoxy Ketone Protease Inhibitors
RU2496486C1 (ru) * 2012-07-11 2013-10-27 Александр Васильевич Иващенко Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение
DK2943189T3 (da) 2013-01-08 2021-04-06 Pathologica Llc Mitoguazon til behandling af progressiv multipel sklerose
WO2014141298A2 (en) * 2013-03-11 2014-09-18 Astron Research Limited Stable pharmaceutical composition of fingolimod
EP2990055B1 (en) * 2013-04-26 2019-06-05 Kyoto University Composition comprising a sphingosine-1-phosphate receptor 1 agonist for inhibiting formation and/or enlargement of cerebral aneurysm or for shrinking it
ES2770500T3 (es) * 2013-05-13 2020-07-01 Synthon Bv Composición farmacéutica que comprende fingolimod
CA2920758A1 (en) * 2013-07-29 2015-02-05 Aizant Drug Research Solutions Pvt Ltd Pharmaceutical compositions of fingolimod
RU2530626C1 (ru) * 2013-10-21 2014-10-10 Ооо "Валента-Интеллект" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
US20170231928A1 (en) * 2014-08-22 2017-08-17 Sunshine Lake Pharma Co., Ltd. Solid composition of fingolimod and preparation thereof
WO2016042493A1 (en) * 2014-09-19 2016-03-24 Aizant Drug Research Pvt. Ltd Pharmaceutical compositions of fingolimod
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
EP3247341A4 (en) * 2015-01-20 2018-12-19 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
US20180042895A1 (en) 2015-02-26 2018-02-15 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
RU2577230C1 (ru) * 2015-04-09 2016-03-10 Общество с ограниченной ответственностью "Лонг Шенг Фарма Рус" Способ получения капсул финголимода гидрохлорида
US9690975B2 (en) 2015-05-28 2017-06-27 Axogen Corporation Quantitative structural assay of a nerve graft
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
EP3419607B1 (en) 2017-03-29 2019-11-20 Deva Holding Anonim Sirketi Stable formulations of fingolimod
GR1009654B (el) 2018-08-31 2019-11-18 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει εναν ανοσοτροποποιητικο παραγοντα και μεθοδος για την παρασκευη αυτου
DE102018217334A1 (de) 2018-10-10 2020-04-16 Harbins Ruhr Bioscience, Inc. Sphingoid-Base und/oder Wirkstoff zur Verwendung bei der Prophylaxe und/oder Therapie einer viralen Infektion und/oder viralen Infektionskrankheit oder der Desinfektion, Nahrungsmittel/Nahrungsergänzungsmittel, Futtermittel/Futterergänzungsmittel und Pflanzenschutzmittel
JP7503420B2 (ja) * 2020-05-18 2024-06-20 東和薬品株式会社 フィンゴリモドを含む医薬組成物とその製造方法及び安定化方法
US11298412B2 (en) 2020-07-16 2022-04-12 Harbins Ruhr Bioscience, Inc. Sphingoid compounds for prophylaxis and/or therapy of coronaviridae infection
AU2021424131A1 (en) * 2021-01-28 2023-07-27 Priothera Limited Methods of treatment with s1p receptor modulators
CA3208122A1 (en) * 2021-01-28 2022-08-04 Priothera Sas Methods of treatment with s1p receptor modulators

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7607683A (nl) * 1976-07-12 1978-01-16 Akzo Nv Werkwijze ter bereiding van nieuwe peptiden en peptide-derivaten en de toepassing hiervan.
US4110332A (en) * 1977-05-05 1978-08-29 Chevron Research Company 1-Triorganostannyl-3-organothio-4-substituted-1,2,4-delta2 -triazolidin-5-ones
US4559153A (en) 1983-10-25 1985-12-17 Phillips Petroleum Company Metal working lubricant
US5112616A (en) * 1988-11-30 1992-05-12 Schering Corporation Fast dissolving buccal tablet
JP2841857B2 (ja) * 1990-11-29 1998-12-24 田辺製薬株式会社 長期間安定な経口用医薬製剤
US5604229A (en) 1992-10-21 1997-02-18 Yoshitomi Pharmaceutical Industries, Ltd. 2-amino-1,3-propanediol compound and immunosuppressant
DE69524962D1 (de) 1994-08-22 2002-02-14 Welfide Corp Benzolderivate und deren medizinische verwendung
SI0812588T1 (en) 1995-12-28 2005-02-28 Mitsubishi Pharma Corporation Pharmaceutical external preparations for topical administration comprising 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol for the treatment of diseases induced from immune disorder
US6476004B1 (en) * 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
JP2002241272A (ja) 1996-07-18 2002-08-28 Mitsubishi Pharma Corp 医薬処方組成物
JPH11209277A (ja) 1998-01-19 1999-08-03 Yoshitomi Pharmaceut Ind Ltd 医薬組成物
GB9624038D0 (en) 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
PT990440E (pt) * 1997-02-27 2009-02-05 Novartis Ag Composição farmacêutica compreendendo 2-amino-2-[2-(4-octilfenil)etil]propano-1,3-diol, uma lecitina e um sacárido
ES2226110T3 (es) 1997-04-04 2005-03-16 Mitsubishi Pharma Corporation Compuestos de 2-aminopropano-1,3-diol, su uso medico, e intermedios para sintetizarlos.
JPH1180026A (ja) 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
JP3545595B2 (ja) 1998-04-01 2004-07-21 花王株式会社 スフィンゴ糖脂質の製造法
JP4627356B2 (ja) * 1999-06-30 2011-02-09 昭 松森 ウイルス性心筋炎の予防または治療薬剤
EP1195165A4 (en) * 1999-07-12 2005-08-10 Ono Pharmaceutical Co FIBROSIS INHIBITORS CONTAINING THE ACTIVE INGREDIENT OF SPHINGOSINE A PHOSPHATE OR ITS RECEPTOR AGONISTS
NZ533997A (en) 2000-07-13 2005-11-25 Sankyo Co Amino alcohol derivatives
WO2002018395A1 (en) 2000-08-31 2002-03-07 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents
US6953332B1 (en) 2000-11-28 2005-10-11 St. Jude Medical, Inc. Mandrel for use in forming valved prostheses having polymer leaflets by dip coating
DK1377593T3 (da) 2001-03-26 2006-04-10 Novartis Ag 2-Amino-propanolderivater
US7521192B2 (en) * 2001-04-18 2009-04-21 Rigel Pharmaceuticals, Inc. EDG: modulators of lymphocyte activation and migration
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
US20040235794A1 (en) 2001-09-04 2004-11-25 Shinji Nakade Remedies for respiratory diseases comprising sphingosine-1-phosphate receptor controller
JP4152884B2 (ja) 2001-09-27 2008-09-17 杏林製薬株式会社 ジアリールエーテル誘導体とその付加塩及び免疫抑制剤
MXPA04002679A (es) 2001-09-27 2004-07-30 Kyorin Seiyaku Kk Derivados de sulfuro de diarilo, sales de los mismos y agentes inmunosupresores que utilizan los mismos.
EP1469863A2 (en) 2002-01-18 2004-10-27 Merck & Co., Inc. Selective s1p1/edg1 receptor agonists
EP1575964B1 (en) 2002-01-18 2009-11-11 Merck & Co., Inc. N-(benzyl)aminoalkyl carboxylate, phosphinates, phosphonates and tetrazoles as edg receptor agonists
US7479504B2 (en) 2002-01-18 2009-01-20 Merck & Co., Inc. Edg receptor agonists
EP1513522A2 (en) 2002-01-18 2005-03-16 Sri International Methods of treating conditions associated with an edg receptor
WO2006009092A1 (ja) * 2004-07-16 2006-01-26 Kyorin Pharmaceutical Co., Ltd. 効果的な医薬の使用法及び副作用発現の防御に関する方法

Also Published As

Publication number Publication date
IL197578A (en) 2015-10-29
GR20040100121A (el) 2004-12-17
HUS1100016I1 (hu) 2016-08-29
HUE028247T2 (en) 2016-12-28
SG175449A1 (en) 2011-11-28
PE20131352A1 (es) 2013-11-14
US20170290787A1 (en) 2017-10-12
HK1155647A1 (en) 2012-05-25
EP1613288B1 (en) 2008-11-19
RU2475237C2 (ru) 2013-02-20
AU2004228929A1 (en) 2004-10-21
ES2228282A1 (es) 2005-04-01
ES2320767T3 (es) 2009-05-28
PE20150676A1 (es) 2015-05-17
US20110105620A1 (en) 2011-05-05
BE2011C030I2 (cg-RX-API-DMAC10.html) 2023-03-07
RU2012148593A (ru) 2014-05-20
EP2316431B1 (en) 2015-09-30
FR2854073B1 (fr) 2008-03-14
HRP20050886B1 (en) 2011-01-31
IS2682B (is) 2010-10-15
IS8114A (is) 2005-11-01
RU2010147000A (ru) 2012-08-10
ITMI20040682A1 (it) 2004-07-06
AR078781A2 (es) 2011-11-30
NO20131287L (no) 2006-01-09
JP5543298B2 (ja) 2014-07-09
CA2521325C (en) 2010-09-14
US20090203798A1 (en) 2009-08-13
LU91867I9 (cg-RX-API-DMAC10.html) 2019-01-03
CN1767819B (zh) 2010-07-28
HRP20100600A2 (hr) 2011-03-31
IS8885A (is) 2010-02-25
PE20090743A1 (es) 2009-07-17
FR11C0036I2 (fr) 2023-12-29
CN1767819A (zh) 2006-05-03
IE20040246A1 (en) 2004-12-15
HRP20100601B1 (hr) 2016-12-02
DE122011100047I1 (de) 2011-12-15
US20140011885A1 (en) 2014-01-09
AT504853A2 (de) 2008-08-15
ES2556947T3 (es) 2016-01-21
CY1117071T1 (el) 2017-04-05
PL1613288T3 (pl) 2009-07-31
PE20130200A1 (es) 2013-03-09
EP2008650A3 (en) 2011-04-27
RU2475236C2 (ru) 2013-02-20
MA27729A1 (fr) 2006-01-02
US8324283B2 (en) 2012-12-04
NO20055231L (no) 2006-01-09
PL2316431T3 (pl) 2016-09-30
KR20050121712A (ko) 2005-12-27
HRP20100601A2 (hr) 2011-03-31
DK1613288T3 (da) 2009-03-23
RU2005134173A (ru) 2006-09-10
CY1110260T1 (el) 2014-04-09
CA2521325A1 (en) 2004-10-21
NO20100250L (no) 2006-01-09
DE202004021680U1 (de) 2010-04-22
TW200503784A (en) 2005-02-01
NO329332B1 (no) 2010-09-27
GR1005052B (el) 2005-11-30
RU2009105403A (ru) 2010-08-27
MXPA05010860A (es) 2006-05-25
HRP20050886A2 (en) 2006-11-30
JP2013177404A (ja) 2013-09-09
GB0407819D0 (en) 2004-05-12
TNSN05256A1 (en) 2007-07-10
RU2358716C2 (ru) 2009-06-20
AT501681B1 (de) 2012-04-15
TWI332847B (en) 2010-11-11
DE102004016947A1 (de) 2004-10-21
LU91867I2 (fr) 2011-11-08
NO2011016I1 (no) 2011-09-19
US20060275357A1 (en) 2006-12-07
KR101367574B1 (ko) 2014-02-25
CN101797241B (zh) 2013-03-27
EP2316431A1 (en) 2011-05-04
HK1071685A1 (en) 2005-07-29
MY141249A (en) 2010-03-31
BRPI0409250B1 (pt) 2017-07-11
GB2400318A (en) 2004-10-13
US20130108675A1 (en) 2013-05-02
BRPI0409250B8 (pt) 2022-01-18
NO2011016I2 (no) 2012-08-27
KR20110005320A (ko) 2011-01-17
CN101797241A (zh) 2010-08-11
DE602004017847D1 (de) 2009-01-02
US20080311188A1 (en) 2008-12-18
NO334116B1 (no) 2013-12-16
RU2010146697A (ru) 2012-05-27
EP2319502A1 (en) 2011-05-11
CY2011013I2 (el) 2014-04-09
JP2004307506A (ja) 2004-11-04
BRPI0409250A (pt) 2006-03-28
IL170888A (en) 2010-06-16
NZ592339A (en) 2012-09-28
ATE414508T1 (de) 2008-12-15
PT1613288E (pt) 2009-02-25
CA2707750A1 (en) 2004-10-21
US20190175527A1 (en) 2019-06-13
FR11C0036I1 (fr) 2011-10-14
NO20055231D0 (no) 2005-11-07
ES2228282B1 (es) 2006-02-16
EP1613288A1 (en) 2006-01-11
SI1613288T1 (sl) 2009-04-30
NO335120B1 (no) 2014-09-22
ECSP056090A (es) 2006-03-01
AT501681A1 (de) 2006-10-15
DK2316431T3 (en) 2016-01-11
GB2400318B (en) 2005-08-10
NZ542622A (en) 2009-01-31
US20140255497A1 (en) 2014-09-11
CY2011013I1 (el) 2014-04-09
WO2004089341A1 (en) 2004-10-21
IL197578A0 (en) 2011-07-31
PE20050396A1 (es) 2005-07-05
EP2008650A2 (en) 2008-12-31
JP2011006461A (ja) 2011-01-13
US20220031609A1 (en) 2022-02-03
ZA200507394B (en) 2007-03-28
US20200237690A1 (en) 2020-07-30
NZ586280A (en) 2011-12-22
AR078782A2 (es) 2011-11-30
SI2316431T1 (sl) 2016-04-29
BE1015972A5 (fr) 2005-12-06
CL2011000450A1 (es) 2011-11-25
HK1091114A1 (en) 2007-01-12
CL2004000745A1 (es) 2005-02-11
FR2854073A1 (fr) 2004-10-29
JP5495467B2 (ja) 2014-05-21
KR20120101148A (ko) 2012-09-12
AU2004228929B2 (en) 2008-02-07
EP2769713A1 (en) 2014-08-27
IL242037A0 (en) 2015-11-30

Similar Documents

Publication Publication Date Title
AR043987A1 (es) Composiciones farmaceuticas para administracion oral de agonistas del receptor de fosfato de esfingosina-1
ECSP003682A (es) Compuestos para el tratamiento de la isquemia
PE20081569A1 (es) Metodo para el tratamiento de sindrome del intestino irritable predominante-diarrea
CL2011000835A1 (es) Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras.
CR10288A (es) Pirazoles como inhibidores de la 11-beta-hsd1
PA8557101A1 (es) Benzimidazoles
BRPI0514474A (pt) multiparticulados
PE20060464A1 (es) Composicion farmaceutica que comprende flibanserina para el tratamiento de trastornos sexuales
BRPI0409133A (pt) formulações farmacêuticas contendo metilnaltrexona
CL2011000144A1 (es) Compuestos derivados de benzo (1,4) dioxin-2-ilmetil-sulfamida; composiciones farmaceuticas que los contienen; proceso para prepararlos y uso en el tratamiento de la ansiedad, epilepsia, dolor, abuso de sustancias, trastornos relacionados, entre otros.
UY31406A1 (es) &#34;producto de dispersion solida que contiene un compuesto a base de n-aril urea&#34;.
PE20100149A1 (es) Composiciones farmaceuticas a base de agonistas del receptor s1p
CL2008001104A1 (es) Compuestos derivados de [1,2,3]triazolo[4,5-b]piridin-carboxamidas y [1,2,3]triazolo[4,5-d]pirimidin-carboxamidas, inhibidores de mgl y faah; procedimiento de preparacion; composicion farmaceutica; y su uso en el tratamiento de delolores agudos o cronicos, vertigos, vomitos, nauseas, sindrome metaloico, dispipidemia, entre otros.
ECSP055729A (es) Nuevos inhibidores biciclicos de la lipasa sensible a hormonas
ECSP22040921A (es) Composición farmacéutica que comprende selexipag
CR11096A (es) Extrudidos con enmascaramiento del sabor mejorado
EA200601901A1 (ru) Композиции, содержащие иммуномодулирующие соединения для лечения и управления течением миелодиспластических синдромов и способы с их использованием
PE20070521A1 (es) 7-[2-[4-(6-FLUORO-3-METIL-1,2-BENCISOXAZOL-5-IL)-1-PIPERAZINIL]ETIL]-2-(1-PROPINIL)-7H-PIRAZOL-[4,3-E]-[1,2,4]-TRIAZOL-[1,5-C]-PIRIMIDIN-5-AMINA COMO ANTAGONISTA DEL RECEPTOR DE ADENOSINA A2a
AR018102A1 (es) Utilizacion de combinaciones farmaceuticas de al menos un antiemetico de eficacia procinetica, o de sales de aceptacion farmaceutica del mismo, ytramadol, sus enantiomeros o las sales de aceptacion farmaceutica, dichas combinaciones farmaceuticas y los medicamentos que contienen dichas combinaciones
ES2581331T3 (es) Inhibidor de la progresión de una enfermedad atribuida a una acumulación anormal de grasa hepática
UY28979A1 (es) Derivados de hidrocloruros de 3-carboxamida, composiciones farmacéuticas que los contienen, procedimiento de preparación y su uso, útiles como inhibidores selectivos de gsk3
AR045912A1 (es) Composiciones farmaceuticas que contienen derivados de azetidina
PA8799801A1 (es) 1,2,4-triazoles trisustituidos
AR056517A1 (es) Composiciones y metodos farmaceuticos utilizando temozolomida y un inhibidor de la proteina quinasa
CL2008002289A1 (es) Compuestos derivados de n-heteroaril-carboxamidas triciclicas; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para tratar dolor, inflamacion, trastornos metabolicos, trastornos urologicos, entre otros.

Legal Events

Date Code Title Description
FC Refusal